<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03954171</url>
  </required_header>
  <id_info>
    <org_study_id>19 GENF 01</org_study_id>
    <nct_id>NCT03954171</nct_id>
  </id_info>
  <brief_title>Platino-resistance in Ovarian Cancer</brief_title>
  <acronym>PlatinOv</acronym>
  <official_title>Platino-resistance in Ovarian Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut Claudius Regaud</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut Claudius Regaud</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective, monocentric study aiming to identify factors involved in platinum
      based-chemotherapy resistance in patients with epithelial ovarian cancer (all stages).

      Patients will receive treatment (platinum based-chemotherapy) according to the standard
      practices.

      A prospective database and an associated biological collection will be performed during 5
      years:

        -  For each patient: clinical, biological, epidemiological and therapeutic treatment data
           will be collected during the standard therapeutic care.

        -  Biological samples (blood samples, tumor biopsy specimens and ascites samples) will be
           collected for all patients. These samples will be collected at the same time as those
           taken in standard practice (no additional biopsy will be performed for the study).

      Study participation of each patient will be 5 years.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 6, 2020</start_date>
  <completion_date type="Anticipated">May 2029</completion_date>
  <primary_completion_date type="Anticipated">May 2029</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The rate of patients alive without progression</measure>
    <time_frame>5 years for each patient</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The time to onset of platinum based-chemotherapy resistance</measure>
    <time_frame>5 years for each patient</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Epithelial Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Patients treated with platinum based-chemotherapy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Patients treated with platinum based-chemotherapy</intervention_name>
    <description>Blood samples, tumor biopsy specimens and ascites samples will be collected at different time points (if feasible, according to the samples taken in the standard practice):
before treatment initiation (blood sample),
during hospitalisation for surgery (blood sample),
during follow-up consultations (blood sample).
If tumor biopsy and/or ascites sampling are performed during the standard care, a sample will be collected for the study.</description>
    <arm_group_label>Patients treated with platinum based-chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years old

          2. Epithelial ovarian cancer at initial diagnosis (all stages)

          3. Curative treatment (exeresis surgery) not yet initiated excepted neo-adjuvant
             treatment

          4. Indication of platinum based-chemotherapy

          5. Patient affiliated to the french social security system

          6. Patient must provide written informed consent prior to inclusion in the study and any
             study-specific procedure

        Exclusion Criteria:

          1. Non-epithelial ovarian tumor, borderline ovarian tumor

          2. Patient with recurrent disease

          3. Exploratory surgery not performed at the &quot;Institut Universitaire du Cancer de Toulouse
             - Oncopole (IUCT-O)&quot;

          4. Pregnant or breastfeeding women

          5. Any psychological, familial, geographical or sociological condition potentially
             preventing the medical follow-up and/or study procedures

          6. Patient who has forfeited his/her freedom by administrative or legal award or who is
             under legal protection (curatorship and guardianship, protection of justice)
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Gwenaël FERRON</last_name>
    <phone>05 31 15 53 55</phone>
    <email>Ferron.Gwenael@iuct-oncopole.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Institut Universitaire du Cancer de Toulouse - Oncopole</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gwenaël FERRON</last_name>
      <phone>05 31 15 53 55</phone>
      <email>Ferron.Gwenael@iuct-oncopole.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 15, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 17, 2019</study_first_posted>
  <last_update_submitted>May 7, 2020</last_update_submitted>
  <last_update_submitted_qc>May 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Epithelial Ovarian Cancer</keyword>
  <keyword>Platinum based-chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

